A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Chronic dosing effects of propranolol in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Species comparison of interleukin-13 induced airway hyperreactivity as model for allergic asthma Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
The effect of vitamin D therapy on airway reactivity and airway inflammation in asthmatic children Source: Annual Congress 2013 –Preschool wheeze Year: 2013
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014